166 related articles for article (PubMed ID: 18346113)
1. Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours.
Häyry V; Tynninen O; Haapasalo HK; Wölfer J; Paulus W; Hasselblatt M; Sariola H; Paetau A; Sarna S; Niemelä M; Wartiovaara K; Nupponen NN
Neuropathol Appl Neurobiol; 2008 Oct; 34(5):555-63. PubMed ID: 18346113
[TBL] [Abstract][Full Text] [Related]
2. Expression of the Polycomb-Group protein BMI1 and correlation with p16 in astrocytomas an immunohistochemical study on 80 cases.
Tirabosco R; De Maglio G; Skrap M; Falconieri G; Pizzolitto S
Pathol Res Pract; 2008; 204(9):625-31. PubMed ID: 18450386
[TBL] [Abstract][Full Text] [Related]
3. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
4. Copy number alterations of the polycomb gene BMI1 in gliomas.
Häyry V; Tanner M; Blom T; Tynninen O; Roselli A; Ollikainen M; Sariola H; Wartiovaara K; Nupponen NN
Acta Neuropathol; 2008 Jul; 116(1):97-102. PubMed ID: 18427816
[TBL] [Abstract][Full Text] [Related]
5. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma.
Mihic-Probst D; Kuster A; Kilgus S; Bode-Lesniewska B; Ingold-Heppner B; Leung C; Storz M; Seifert B; Marino S; Schraml P; Dummer R; Moch H
Int J Cancer; 2007 Oct; 121(8):1764-70. PubMed ID: 17597110
[TBL] [Abstract][Full Text] [Related]
6. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells.
Song LB; Zeng MS; Liao WT; Zhang L; Mo HY; Liu WL; Shao JY; Wu QL; Li MZ; Xia YF; Fu LW; Huang WL; Dimri GP; Band V; Zeng YX
Cancer Res; 2006 Jun; 66(12):6225-32. PubMed ID: 16778197
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.
Ranuncolo SM; Varela M; Morandi A; Lastiri J; Christiansen S; Bal de Kier Joffé E; Pallotta MG; Puricelli L
J Neurooncol; 2004 Jun; 68(2):113-21. PubMed ID: 15218947
[TBL] [Abstract][Full Text] [Related]
8. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions.
Breuer RH; Snijders PJ; Sutedja GT; Sewalt RG; Otte AP; Postmus PE; Meijer CJ; Raaphorst FM; Smit EF
Lung Cancer; 2005 Jun; 48(3):299-306. PubMed ID: 15892997
[TBL] [Abstract][Full Text] [Related]
9. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression.
Vonlanthen S; Heighway J; Altermatt HJ; Gugger M; Kappeler A; Borner MM; van Lohuizen M; Betticher DC
Br J Cancer; 2001 May; 84(10):1372-6. PubMed ID: 11355949
[TBL] [Abstract][Full Text] [Related]
10. Ezrin expression in tissue microarray of primary and recurrent gliomas.
Tynninen O; Carpén O; Jääskeläinen J; Paavonen T; Paetau A
Neuropathol Appl Neurobiol; 2004 Oct; 30(5):472-7. PubMed ID: 15488023
[TBL] [Abstract][Full Text] [Related]
11. FGF2 as a potential prognostic biomarker for proneural glioma patients.
Sooman L; Freyhult E; Jaiswal A; Navani S; Edqvist PH; Pontén F; Tchougounova E; Smits A; Elsir T; Gullbo J; Lennartsson J; Bergqvist M; Ekman S
Acta Oncol; 2015 Mar; 54(3):385-94. PubMed ID: 25263081
[TBL] [Abstract][Full Text] [Related]
12. Twist predicts poor outcome of patients with astrocytic glioma.
Nordfors K; Haapasalo J; Mäkelä K; Granberg KJ; Nykter M; Korja M; Paavonen T; Haapasalo H; Soini Y
J Clin Pathol; 2015 Nov; 68(11):905-12. PubMed ID: 26163539
[TBL] [Abstract][Full Text] [Related]
13. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
14. Expression of cell cycle inhibitors p21, p27, p14 and p16 in gliomas. Correlation with classic prognostic factors and patients' outcome.
Zolota V; Tsamandas AC; Aroukatos P; Panagiotopoulos V; Maraziotis T; Poulos C; Scopa CD
Neuropathology; 2008 Feb; 28(1):35-42. PubMed ID: 18181833
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Shono T; Tofilon PJ; Bruner JM; Owolabi O; Lang FF
Cancer Res; 2001 Jun; 61(11):4375-81. PubMed ID: 11389063
[TBL] [Abstract][Full Text] [Related]
16. P53 gene mutation and expression of MDM2, P53, P16 protein and their relationship in human glioma.
Cui W; Wu R; Cao H; Gao J; Wang X; Ren Q
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(6):622-4, 635. PubMed ID: 16696307
[TBL] [Abstract][Full Text] [Related]
17. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma.
Yang GF; He WP; Cai MY; He LR; Luo JH; Deng HX; Guan XY; Zeng MS; Zeng YX; Xie D
BMC Cancer; 2010 Apr; 10():133. PubMed ID: 20377880
[TBL] [Abstract][Full Text] [Related]
18. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of histologic grading, the cell cycle-associated antigen Ki-S1 and cell cycle regulators in malignant fibrous histiocytomas: a multivariate analysis.
Brinck U; Cordon-Cardo C; Korabiowska M; Kellner S; Trybus-Galuszka H; Stachura J; Parwaresch MR; Schauer A
Verh Dtsch Ges Pathol; 1998; 82():232-8. PubMed ID: 10095440
[TBL] [Abstract][Full Text] [Related]
20. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
